GlaxoSmithKline keeps trucking alongside AI with new, multi-year pathology partnership with Boston outfit
Big Pharma has been in hot pursuit of the allure of AI integration, with the alleged potential for revolutionizing drug R&D. The UK’s GlaxoSmithKline has been no exception, with its partnerships in the past with King’s College for personalized oncology treatments and with Cerebras for access to its superAI platform.
Introduce Boston AI biotech PathAI. After already aligning arms with Bristol Myers Squibb, the six-year-old startup is linking up with GSK. It’s a big get for PathAI, which closed a Series B in 2019, bagging $75 million in the process and, two years later, $165 million in a Series C.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.